CD19 and myeloid sarcoma: After the second OFA administration, complete CD20+ (both CD3+ and CD19+) cell depletion in the peripheral blood was achieved in all MS patients, and this persisted after 3 months of OFA treatment, leading to a significant reduction of the absolute lymphocyte count in the peripheral blood [18].